搜尋結果
Dezember Pfizer und BioNTech erhalten von der FDA eine Notfallzulassung für die sogenannte Booster-Dosis gegen COVID-19 für Personen ab 16 Jahren. 2021. 29. November Die EU-Kommission erteilt die Zulassungserweiterung für den COVID-19-Impfstoff für die Anwendung bei 5- bis 11-Jährigen. 2021.
El análisis de eficacia primario demostró que la vacuna tiene una eficacia del 95% contra COVID-19 a partir de 28 días después de la primera dosis. El 11 de diciembre de 2020, la vacuna de Pfizer-BioNTech para COVID-19 no ha sido aprobada ni autorizada por la Food and Drug Administration de EE. UU. (FDA), pero ha sido autorizada para uso de ...
2021年3月11日 · The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. The vaccine has now been granted a conditional marketing authorization, emergency use authorization or temporary authorization in a total of more than 60 countries.
2023年6月23日 · Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is FDA authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome ...
2020年12月31日 · The World Health Organization (WHO) today listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO since the outbreak began a year ago.The WHO’s Emergency Use Listing (EUL) opens the door for countries to expedite their own regulatory approval processes to import and administer the vaccine. It also ...
2020年9月8日 · Pfizer and BioNTech are committed to decreasing health disparities in underrepresented populations through the clinical trial process. To that end, many investigator sites are in diverse communities that have been disproportionately affected by COVID-19 so that individuals who have been most impacted have the opportunity to participate.
El Grupo de Expertos en Asesoramiento Estratégico sobre inmunización (SAGE) de la OMS ha publicado recomendaciones provisionales relativas al uso de la vacuna contra la COVID-19 de Pfizer BioNTech (BNT162b2). En el presente artículo se sintetizan esas recomendaciones provisionales. Véase el documento completo aquí.
